Dr Boreham's Crucible: It's a long way to the top if you want to roll prostate cancer, but Clarity is a clear contender

Dr Boreham's Crucible: It's a long way to the top if you want to roll prostate cancer, but Clarity is a clear contender

There’s nothing like a great biotech rivalry, such as the one between radio-pharmaceutical peers Clarity Pharmaceuticals (ASX:CU6) and Telix Pharmaceuticals (ASX:TLX). Raising the stakes, Clarity executive chairman Dr Alan Taylor makes a bare-all promise pertaining to Telix’s proposed prostate cancer therapy TLX-591. “I’m willing to say that if that gets to market, I will run down (Sydney’s) Pitt Street with no clothes on,” he says. Taylor’s ‘nu…